GSK gets expanded FDA approval for Trelegy Ellipta to treat asthma and COPD
Trelegy Ellipta is a combination of three molecules, fluticasone furoate, umeclidinium and vilanterol (FF/UMEC/VI) for once-daily single inhalation
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Sep 20
Trelegy Ellipta is a combination of three molecules, fluticasone furoate, umeclidinium and vilanterol (FF/UMEC/VI) for once-daily single inhalation
10 Sep 20
Of the total fine levied by the French competition watchdog totalling €444m, Novartis is expected to pay €385m…
09 Sep 20
Takeda is expected to receive around $562m in an upfront payment, subject to customary legal and regulatory closing…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Sep 20
The UK-based drugmaker has voluntarily paused the clinical trials to ensure the review of safety data by an…
08 Sep 20
The clinical trial in Germany will evaluate the safety and efficacy of potential Covid-19 vaccine candidate BNT162b2 in…
08 Sep 20
Alkahest is a wholly-owned subsidiary within the Grifols innovation office (GIANT) and is focused on proteins with a…
07 Sep 20
Gavreto is a once-daily, oral precision therapy, designed to specifically act against RET alterations, fusions and mutations, irrespective…
04 Sep 20
AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint,…
04 Sep 20
Sanofi and GSK are scaling up the manufacturing of the antigen and adjuvant with the target of producing…
03 Sep 20
Janssen’s decision is based on results from the interim analyses of the Phase 3 clinical study of Pimodivir…